報價延遲最少15分鐘:2026/04/26 04:11 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.68 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.59/-0.26
|
|
企業價值
202.33M
|
| 資產負債 |
|
每股賬面淨值
0.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
149.16M
|
|
每股收益
1.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services. |
